Abstract
To evaluate the accuracy of positron emission tomography/computed tomography (PET/CT) in the diagnosis of lymph node metastasis in non-small cell lung cancer (NSCLC) by a method of meta-analysis. A comprehensive search of PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Embase data bases was conducted to collect literature about PET/CT diagnosing lymph node metastasis of NSCLC up to December 1, 2021. Stata 15.0 software was used for the calculation of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The publication bias was evaluated by Deeks' funnel plot. A total of 25 studies were enrolled, including 2,458 patients with NSCLC. The pooled sensitivity of PET/CT for diagnosing lymph node metastasis in NSCLC was 0.68 (95%CI: 0.61-0.75), the pooled specificity being 0.93 (95%CI: 0.89-0.95). Likelihood ratio syntheses gave an overall PLR of 9.4 (95%CI: 6.3-13.9), and NLR of 0.34 (95%CI: 0.28-0.41). The pooled DOR was 28 (95%CI: 19-40). The summary receiver operating characteristic curve showed the area under the curve of 0.88 (95%CI: 0.84-0.90). Positron emission tomography/CT has a good value in the diagnosis of lymph node metastasis of NSCLC, with specificity excellent. Positron emission tomography/CT can be used as one of the main imaging diagnosis methods for lymph node metastasis in patients with NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
